# Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition
Canonical URL: https://biopharmsignal.com/news/ARVN/arvinas-presents-preclinical-data-supporting-mechanistic-synergies-and-enhanced-antitumor-activity-with-the-combination-of-arv-393-and-glofitamab-at-the-2025-american-society-of-hematology-annual-meeting-and-exposition
Ticker: ARVN
Company: Arvinas, Inc.
Source: Arvinas, Inc.
Published: 2025-12-06 13:05 EST
Original Source URL: https://ir.arvinas.com
## Summary

– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a chemotherapy-free combination approach in diffuse large B-cell lymphoma (DLBCL); initiation expected in 2026 – NEW HAVEN, Conn., Dec.

## Article Body
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a chemotherapy-free combination approach in diffuse large B-cell lymphoma (DLBCL); initiation expected in 2026 – NEW HAVEN, Conn., Dec.
## Recent Company News
- 2026-06-04 12:00 EST — [Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease](https://biopharmsignal.com/news/ARVN/arvinas-joins-the-michael-j-fox-foundation-s-lite-and-ppmi-programs-to-advance-new-therapies-targeting-lrrk2-for-parkinson-s-disease) — Source: Arvinas, Inc.
- 2026-05-29 20:01 EST — [Arvinas to Present at Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/ARVN/arvinas-to-present-at-jefferies-global-healthcare-conference) — Source: Arvinas, Inc.
- 2026-05-18 14:30 EST — [Arvinas Employees Give Back During Company-wide Impact Day](https://biopharmsignal.com/news/ARVN/arvinas-employees-give-back-during-company-wide-impact-day) — Source: Arvinas, Inc.
- 2026-05-12 11:05 EST — [Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/ARVN/arvinas-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Arvinas, Inc.
- 2026-05-12 11:00 EST — [Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)](https://biopharmsignal.com/news/ARVN/arvinas-and-pfizer-enter-into-a-transaction-with-rigel-pharmaceuticals-for-the-exclusive-global-rights-of-veppanu-vepdegestrant) — Source: Arvinas, Inc.
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)